Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Pooled result · HbA1cResult — go to the resultMD −0.40 % 95% CI −0.44 to −0.36Authors' conclusion
SGLT2i not only significantly improved glycated hemoglobin and body weight in patients with T1DM but also significantly increased the risk of diabetic ketoacidosis acidosis.
Study context
- Population
- Insulin-using patients with T1D; RCTs in PubMed, Scopus, Cochrane Library, Web of Science and Embase up to June 30, 202416 articles
- Comparison
- SGLT2i vs placebo
- Outcome
- HbA1c
Pooled result
As reported in the abstract
MD
−0.40 %
95% CI −0.44 to −0.36
P < 0.00001
SGLT2ivs Placebo
MD −0.40 % (95% CI −0.44 to −0.36); P < 0.00001
Further pooled results
| Outcome | MD (kg) (95% CI) | P value | |
|---|---|---|---|
| Body weightI2 = 70% | −3.31 (−3.67 to −2.96) | P < 0.00001 | |
| −4−202Difference, kg (linear scale) |
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| DKAI2 = 0% | 4.45 (2.81–7.05) | P < 0.00001 | |
| 0.10.31310Relative risk (log scale) |
Hypoglycaemia and severe hypoglycaemia
- SGLT2i did not significantly increase the risk of hypoglycemia and severe hypoglycemia vs placebo
Original publication
Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →